UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) **September 22, 2026**

GE HEALTHCARE TECHNOLOGIES INC.
(Exact name of registrant as specified in its charter)

Delaware	**001-41528**	**88-2515116**
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

500 W. Monroe Street, Chicago, IL	**60661**
(Address of principal executive offices)	(Zip Code)

(Registrant's telephone number, including area code) **(833) 735-1139**

____
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.01 per share	GEHC	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 22, 2026, the Board of Directors (the "Board") of GE HealthCare Technologies Inc. (the "Company") appointed Pascal Desroches to serve as a director of the Company, effective January 4, 2027. The Board also appointed Mr. Desroches as a member of the Audit Committee and the Talent, Culture, and Compensation Committee of the Board, effective January 4, 2027.

Upon joining the Board, Mr. Desroches will receive compensation in accordance with the Company's compensation program for non-employee directors, which is described in the Company's Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission (the "SEC") on March 19, 2026. The Company will also enter into an indemnification agreement with Mr. Desroches. The form of indemnification agreement is included as Exhibit 10.3 to the Company's Annual Report on Form 10-K filed with the SEC on February 4, 2026.

There is no arrangement or understanding between Mr. Desroches and any other person pursuant to which he was selected as a director. There are no transactions between Mr. Desroches and the Company that would be reportable under Item 404(a) of Regulation S-K.

Item 7.01 Regulation FD Disclosure.

On September 22, 2026, the Company issued a press release announcing the appointment of Pascal Desroches to its Board. A copy of the press release is furnished as Exhibit 99.

The information furnished pursuant to Item 7.01, including Exhibit 99, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit	**Description**
99	Press Release of GE HealthCare Technologies Inc., dated September 22, 2026.
104	The cover page of this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	GE HealthCare Technologies Inc.
	(Registrant)
Date: September 22, 2026	/s/ Frank R. Jimenez
	Frank R. Jimenez, General Counsel and Corporate Secretary (authorized signatory)

GE HealthCare appoints veteran finance executive Pascal Desroches to Board of Directors

CHICAGO, IL — September 22, 2026 — GE HealthCare (Nasdaq: GEHC) today announced the appointment of Pascal Desroches, Senior Executive Vice President and Chief Financial Officer (CFO) of AT&T (NYSE: T), a Fortune 50 company, to its Board of Directors, effective January 4, 2027. Mr. Desroches brings more than 30 years of leadership experience across finance, governance, and large-scale technology and digital transformation.

“Pascal is a highly respected executive and accomplished financial leader whose experience spans corporate strategy, capital deployment, and investor engagement,” said H. Lawrence Culp, Jr., Chairman of the Board of Directors, GE HealthCare. “His perspective will further strengthen our Board as we execute on our strategy to advance precision care, accelerate our next wave of innovation, and create long-term value for patients, customers, and shareholders.”

Mr. Desroches has served as CFO of AT&T since 2021 and plans to retire from the company on December 31, 2026. Previously, he served as CFO of WarnerMedia following AT&T’s acquisition of Time Warner in 2018, overseeing financial operations, global real estate, and technology across HBO, Turner Broadcasting, and Warner Bros. As CFO of Turner Broadcasting, he played a pivotal role in the spin-off of three multi-billion-dollar subsidiaries: Time Warner Cable, AOL, and Time.

Earlier in his career, Mr. Desroches worked at KPMG and the U.S. Securities and Exchange Commission, gaining broad industry and regulatory experience. He serves on the boards of Honeywell Aerospace, where he chairs the audit committee, and the Federal Reserve Bank of Dallas. He also brings healthcare governance experience through nearly four years of service on the board of DaVita.

“As a global leader in precision care, GE HealthCare plays a critical role in shaping the future of healthcare and improving outcomes for patients worldwide,” said Pascal Desroches. “I look forward to serving on the Board and working with the management team to advance the company’s strategy, make care more personal and precise, drive growth, and create long-term value.”

Investor Relations Contact:

Carolynne Borders

+1-631-662-4317

carolynne.borders@gehealthcare.com

GE HealthCare Media Contact:

Jennifer Fox
+1 -414530 - 3027
jennifer.r.fox@gehealthcare.com

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world's most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Advanced Imaging Solutions, Pharmaceutical Diagnostics and Patient Care Solutions segments to help clinicians deliver more personalized, precise patient care. We are a $20.6 billion business with approximately 54,000 colleagues working to create a world where healthcare has no limits.

GE HealthCare is proud to be among 2026 *Fortune* World's Most Admired Companies™.

Follow us on LinkedIn, Facebook, Instagram, or visit our website for our latest news and perspectives.